Liquid formulations of pegylated growth hormone

Details for Australian Patent Application No. 2006286486 (hide)

Owner Novo Nordisk Health Care AG

Inventors Reslow, Mats

Agent Shelston IP

Pub. Number AU-A-2006286486

PCT Pub. Number WO2007/025988

Priority 05107917.6 30.08.05 EP

Filing date 30 August 2006

Wipo publication date 8 March 2007

International Classifications

C07K 14/61 (2006.01) Peptides having more than 20 amino acids

A61K 38/27 (2006.01) Medicinal preparations containing peptides - Growth hormone (GH) (Somatotropin)

A61K 47/48 (2006.01) Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives - the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates

Event Publications

28 February 2008 PCT application entered the National Phase

  PCT publication WO2007/025988 Priority application(s): WO2007/025988

9 September 2010 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(a). A direction to request examination has been given for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006286489-Treatment of optic neuritis

2006286476-Novel azabicyclo(3.2.1)oct-2-ene derivatives and their use as monoamine neurotransmitter re-uptake inhibitors